Two cases of bacterial meningitis due to meropenem-resistant Streptococcus pneumoniae: A threat of serotype 35B, ST 558 lineage

J Infect Chemother. 2020 Jul;26(7):745-748. doi: 10.1016/j.jiac.2020.02.013. Epub 2020 Mar 12.

Abstract

Although the pneumococcal conjugate vaccine (PCV) has decreased the incidence of invasive pneumococcal disease (IPD) in children, cases of IPD caused by non-PCV serotypes have been increasing. Here, we report two cases of bacterial meningitis caused by meropenem-resistant Streptococcus pneumoniae; in both the cases, 13-valent PCV (PCV13) had been administered. The isolated S. pneumoniae strains were non-PCV13 serotype 35B and resistant to penicillin G, cefotaxime, and meropenem. In addition, multilocus sequence typing (MLST) revealed the sequence type (ST) to be 558. In case 1, a 6-month-old girl recovered without sequelae after antibiotic therapy comprising cefotaxime and vancomycin, whereas in case 2, a 9-month-old boy was treated with an empirical treatment comprising ceftriaxone and vancomycin administration. However, maintaining the blood concentration of vancomycin within the effective range was difficult, due to which the antibiotics were changed to panipenem/betamipron. During the treatment, he presented with seizures, which were effectively controlled with antiepileptic drugs. The rate of incidence of penicillin-susceptible IPD has been substantially increasing after the introduction of PCV. However, an upsurge in IPD cases due to multidrug-resistant (MDR) serotype 35B has been reported in countries where PCV13 was introduced before introducing in Japan. Moreover, an increase in the proportion of MDR serotype 35B and decrease in the susceptibility to broad-spectrum antimicrobials, including meropenem, have been reported. Hence, the number of meningitis cases caused by MDR serotype 35B/ST558 may increase in the future.

Keywords: Bacterial meningitis; Meropenem-resistant Streptococcus pneumoniae; Serotype 35B.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cefotaxime / pharmacology
  • Cefotaxime / therapeutic use
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Female
  • Humans
  • Infant
  • Male
  • Meningitis, Pneumococcal / blood
  • Meningitis, Pneumococcal / diagnosis
  • Meningitis, Pneumococcal / drug therapy*
  • Meningitis, Pneumococcal / microbiology
  • Meropenem / pharmacology*
  • Meropenem / therapeutic use
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Pneumococcal Vaccines / administration & dosage
  • Serotyping
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / genetics*
  • Streptococcus pneumoniae / isolation & purification
  • Thienamycins / pharmacology
  • Thienamycins / therapeutic use
  • Treatment Outcome
  • beta-Alanine / analogs & derivatives
  • beta-Alanine / pharmacology
  • beta-Alanine / therapeutic use

Substances

  • 13-valent pneumococcal vaccine
  • Anti-Bacterial Agents
  • Pneumococcal Vaccines
  • Thienamycins
  • beta-Alanine
  • panipenem-betamipron
  • Meropenem
  • Cefotaxime